Oncofocus Solutions

CImple: 'All–in–one' Strategic Insights Platform. It seamlessly integrates competitive intelligence (CI) with simplicity, utilizing advanced AI capabilities and automation tools to keep stakeholders well-informed and support their decision-making processes with unparalleled efficiency. Click here to watch the YouTube video - https://lnkd.in/gHKy_6vR #CImple #artificialintelligence #AI #ai #biopharma #oncofocus #oncology #conferenceintelligence #competitiveintelligence

Oncofocus will be attending ESMO - European Society for Medical Oncology Congress 2024! If you plan to be there, our Director, Vikram Reddy Keeshara, will be delighted to meet in person to discuss how Oncofocus can support your competitive intelligence needs. We look forward to connecting with you at the conference! #ESMO #ESMO2024 #ESMOcongress2024 #oncofocus #cgtwatch #cimple #oncology #conferenceintelligence #biopharma

We track over 3,000 unique CAR-T therapies and more than 3,500 CAR-T regimens across a broad spectrum of oncology indications. Through continuous analysis of newly released clinical data, we keep our clients informed about the latest competitive landscape shifts and evolving clinical paradigms, empowering them to make well-informed decisions. Our suite of competitive intelligence (CI) services includes: - Competitive landscape evaluation - Asset/Indication prioritisation - Clinical trial data benchmarking - In-licensing/out-licensing due diligence - Conference coverage reports

Oncofocus will be attending ESMO - European Society for Medical Oncology Congress 2024! If you plan to be there, our Director, Vikram Reddy Keeshara, will be delighted to meet in person to discuss how Oncofocus can support your competitive intelligence needs. We look forward to connecting with you at the conference! #ESMO #ESMO2024 #ESMOcongress2024 #oncofocus #cgtwatch #cimple #oncology #conferenceintelligence #biopharma

We track over 3,000 unique CAR-T therapies and more than 3,500 CAR-T regimens across a broad spectrum of oncology indications. Through continuous analysis of newly released clinical data, we keep our clients informed about the latest competitive landscape shifts and evolving clinical paradigms, empowering them to make well-informed decisions. Our suite of competitive intelligence (CI) services includes: - Competitive landscape evaluation - Asset/Indication prioritisation - Clinical trial data benchmarking - In-licensing/out-licensing due diligence - Conference coverage reports

Ten years ago, Oncofocus began with a bold vision: To transform the oncology consulting landscape by providing unparalleled insights and solutions. Today, as we celebrate our 10th anniversary, we are thrilled to unveil a new chapter in our journey marked by an updated logo and the launch of "All–in–one Strategic Insights Platform: CImple", reaffirming our commitment to staying at the forefront of the industry. Read our press release here - https://lnkd.in/grQY7yrY #pressrelease #CImple #novusai #artificialintelligence #AI #ai #biopharma #oncofocus #oncology #conferenceintelligence #competitiveintelligence

Oncofocus will be at the 2024 ASCO Annual Meeting! If you are attending, then our Director, Vikram Reddy Keeshara would like to connect with you in person and discuss how Oncofocus can assist you with your competitive intelligence needs. We look forward to seeing you at the conference! #ASCO2024 #ASCO24 #oncofocus #oncology #conferenceintelligence #competitiveintelligence #biopharma

Bladder cancer is the most common malignancy of the urinary tract. As of 2022, Bladder Cancer had an incidence of 614,298 patients worldwide, and 220,596 patients succumbed to the disease. While the therapeutic approach to it remained largely unchanged for many years, recent clinical progress has paved the way towards a novel era of diagnosis and management of the disease, with several special designations and two very recent approvals by the US FDA. In December 2023, the FDA approved enfortumab vedotin-ejfv + pembrolizumab for first-line patients with locally advanced/metastatic (la/m) Urothelial Cancer (UC). This combination was previously granted accelerated approval in April 2023 for patients with la/m UC who are ineligible for cisplatin-containing chemotherapy. Further in March 2024, nivolumab + cisplatin + gemcitabine was approved for frontline treatment of unresectable/metastatic cisplatin-eligible UC patients. The current infographic provides a concise overview of the evolving treatment landscape of Bladder Cancer, spotlighting both established and emerging therapeutic approaches. Join us in recognizing May as Bladder Cancer Awareness Month by exploring the evolving strategies in the fight against this disease. Access the full infographic here - https://lnkd.in/grbpvHSG #bladdercancer #cancer #CancerResearch #TreatmentOptions #EmergingTherapies #infographic #oncofocus

Oncofocus will be at the 2024 ASCO Annual Meeting! If you are attending, then our Director, Vikram Reddy Keeshara would like to connect with you in person and discuss how Oncofocus can assist you with your competitive intelligence needs. We look forward to seeing you at the conference! #ASCO2024 #ASCO24 #oncofocus #oncology #conferenceintelligence #competitiveintelligence #biopharma

Rapid CAR-T Platforms: A Top-level Analysis CAR-T therapy has dramatically changed the course of cancer management over the past few years. However, despite this impact, one of the key challenges about the CAR-T therapies is its highly complex and long manufacturing process. With this lengthy manufacturing time and long wait-time, patients face higher chance of disease progression. To address this scenario, many novel platforms which promote rapid production of CAR-Ts are underway. Several steps utilized in conventional CAR-T production are bypassed and replaced with novel strategies to reduce time. The current slide deck comprehensively summarizes such rapid CAR-T production platforms, the therapeutic areas that are being targeted and their development phase. Read full article here - https://lnkd.in/gys-P6AY #CART #FasTCAR #UFCAR #UltraCAR #FLASHCAR #DashCAR #OlyCAR #QuikinCAR #immunosuppressive #tumormicroenvironment #Cellandgenetherapy #cgtwatch #oncofocus #oncology